The U.S. drug maker released a statement on Monday saying that its Keynote - 010 study, a randomized Phase two -
third trial, showed that
patients who were taking two different doses
of Keytruda (FDA - approved two mg / kg dose and treatment dose
of 10 mg / kg given every three weeks) had longer survival compared to those who took docetaxel, the drug widely used for non-small cell
lung cancer (NSCLC).